These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2512049)

  • 1. Synergy of new C-3 substituted cephalosporins and tobramycin against Pseudomonas aeruginosa and Pseudomonas cepacia.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(4):343-9. PubMed ID: 2512049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
    Cabezudo I; Pfaller M; Bale M; Wenzel R
    Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis.
    Aronoff SC; Klinger JD
    J Antimicrob Chemother; 1985 May; 15(5):545-9. PubMed ID: 3924879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin.
    Heilesen AM; Permin H; Koch C; Høiby N
    Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxalactam-tobramycin-resistant Pseudomonas aeruginosa isolates in patients with cystic fibrosis.
    Fitzpatrick SB; Rosenstein BJ
    Clin Pediatr (Phila); 1983 Sep; 22(9):628-30. PubMed ID: 6224623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K; Lapointe JR
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2411-4. PubMed ID: 8585718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Christenson JC; Korgenski EK; Daly JA
    J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of a E-test method to detect bactericidy of beta lactam-aminoglycoside associations against Pseudomonas aeruginosa isolates from cystic fibrosis].
    Massoni-Cristante S; Loiez C; Adriensen B; Husson MO
    Pathol Biol (Paris); 2003 Apr; 51(3):135-42. PubMed ID: 12781793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
    Chan EL; Zabransky RJ
    Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis.
    Hayes D; Feola DJ; Murphy BS; Kuhn RJ; Davis GA
    Am J Health Syst Pharm; 2011 Feb; 68(4):319-22. PubMed ID: 21289326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1991 Apr; 35(4):783-4. PubMed ID: 1906264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of rifampicin on the in-vitro activity of cefpirome or ceftazidime in combination with aminoglycosides against Pseudomonas aeruginosa.
    Valdes JM; Baltch AL; Smith RP; Hammer MC; Ritz WJ
    J Antimicrob Chemother; 1990 Apr; 25(4):575-84. PubMed ID: 2112539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa.
    Neu HC; Chin NX; Novelli A
    Antimicrob Agents Chemother; 1988 Nov; 32(11):1666-75. PubMed ID: 3150915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL; Fiel SB; Mayer-Hamblett N; Ramsey B; Burns JL
    Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.